Neurogenic claudication and root claudication treated with calcitonin. A double-blind trial.
Forty-two patients with either neurogenic claudication or unilateral root claudication were analyzed in a double-blind comparison of salmon calcitonin (SCT) and placebo, receiving either 100 IU SCT or 1 ml saline four times a week for 8 weeks. Five of 20 SCT and one of 22 placebo patients were classified as responders. There was no statistically significant difference between the treatment groups in the proportion of responders. Seven of eighteen of the placebo group who later received salmon calcitonin improved their walking distance. The authors have not established that this is an organic response.
Porter
R W
RW
Doncaster Royal Infirmary, England.
Miller
C G
CG
D001416:Back Pain / Q000150:complications / Q000000981:diagnostic imaging; D002116:Calcitonin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000209:etiology; D008161:Lumbosacral Region; D008297:Male; D008875:Middle Aged; D009192:Myelography; D009422:Nervous System Diseases / Q000150:complications*; D013126:Spinal Nerve Roots; D014057:Tomography, X-Ray Computed
C028815:salmon calcitonin; D002116:Calcitonin